4//SEC Filing
Mallon Mark 4
Accession 0001209191-21-016044
CIK 0001446847other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 4:37 PM ET
Size
10.2 KB
Accession
0001209191-21-016044
Insider Transaction Report
Form 4
Mallon Mark
DirectorChief Executive Officer
Transactions
- Sale
Class A Common Stock
2021-02-26$9.11/sh−22,582$205,722→ 470,605 total - Sale
Class A Common Stock
2021-02-26$9.11/sh−8,093$73,727→ 493,187 total
Footnotes (2)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
Issuer
IRONWOOD PHARMACEUTICALS INC
CIK 0001446847
Entity typeother
Related Parties
1- filerCIK 0001763533
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 4:37 PM ET
- Size
- 10.2 KB